Get the Stockscreener App
0.6536
5.28%
-0.0364
After Hours:
.65
-0.0036
-0.55%
Context Therapeutics Inc stock is traded at $0.6536, with a volume of 41,085.
It is down -5.28% in the last 24 hours and down -18.91% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.69
Open:
$0.7576
24h Volume:
41,085
Relative Volume:
0.09
Market Cap:
$49.02M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.7182
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-21.35%
1M Performance:
-18.91%
6M Performance:
-68.73%
1Y Performance:
-43.17%
1-Day Range:
$0.65
$0.7576
1-Week Range:
$0.65
$0.8981
52-Week Range:
$0.65
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6536 | 49.02M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors - StreetInsider.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.33 Average PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Employees - MSN
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy? - Defense World
Biotech Giant Context Therapeutics Lures Talent with Sweet Stock Rewards - Elblog.pl
Context Therapeutics Awards Buzzy Stock Options to New Talent, Poised for Tumor-Targeting Breakthroughs - Smartphone Magazine
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Strengthens Team with Strategic Equity Compensation Package - StockTitan
CNTX’s Stock Journey: What Investors Need to Know About Context Therapeutics Inc’s Performance - The InvestChronicle
Why Did Warren Buffett Just Sell Investments He's Recommended Millions of Others Buy? - The Globe and Mail
Context Therapeutics to Showcase at Top 2025 Investor Conferences - MSN
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
There's Room to Chase These 3 Stocks Trading Near 52-Week Highs - The Globe and Mail
Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN
Centrexion stock hits 52-week low at $0.9 amid market challenges - MSN
Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Centrexion stock hits 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Unpacking Q3 Earnings: KLA Corporation (NASDAQ:KLAC) In The Context Of Other Semiconductor Manufacturing Stocks - Yahoo Finance
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):